rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CLNN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application
      Nov 12Yahoo FinanceCLNN
      Clene earnings beat by $0.46, revenue fell short of estimates
      Nov 4Investing.comCLNN
      Clene Inc. (CLNN) Tops Q3 Earnings Estimates
      Nov 4Yahoo FinanceCLNN
      Clene submits new drug application for ALS treatment CNM-Au8
      Oct 19Investing.comCLNN
      Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

      Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall 2026 Investor Confe

      Oct 2Yahoo FinanceCLNN
      Clene at Lytham Partners: FDA path could reshape ALS outlook
      Sep 29Investing.comCLNN
      Clene raises $4 million from insiders to fund operations
      Sep 21Investing.comCLNN
      Clene announces insider-led $4 million financing round

      Detailed price information for Clene Inc (CLNN-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailCLNN
      Clene prices $4M registered direct offering at $3.28 per share
      Sep 15Investing.comCLNN
      Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing
      Sep 9Investing.comCLNN

      This is the newest page. Registered accounts read further back.